Methods of making modified viral genomes

US10023845B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10023845-B2
Application numberUS-201615258584-A
CountryUS
Kind codeB2
Filing dateSep 7, 2016
Priority dateMar 30, 2007
Publication dateJul 17, 2018
Grant dateJul 17, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

First claim

Opening claim text (preview).

We claim: 1. A method of making a modified viral genome comprising: a. obtaining the nucleotide sequence of a parent protein encoding sequence of a parent virus b. rearranging synonymous codons from the protein encoding sequence of the parent virus to obtain a modified protein encoding sequence, wherein said rearrangement provides a reduced codon pair bias relative to a mammalian host over the modified protein encoding sequence, in comparison to the encoding region of the parent virus, without changing codon usage of the parent virus, wherein the codon pair bias is calculated by the following formula: CPB = ∑ i = 1 k ⁢ CPSi k - 1 wherein, the codon pair bias (CPB) of a protein encoding sequence is the arithmetic mean of the codon pair scores (CPS) of the individual codon pairs (i) contained within said protein encoding sequence of k codons in length; and wherein the modified protein encoding sequence has a codon pair bias at least 0.05 less than the codon pair bias of the parent protein encoding sequence c. substituting the modified protein encoding sequence having the rearranged codons into the nucleotide sequence of the parent virus to create a modified viral genome; and d. synthesizing the modified viral genome. 2. The method of claim 1 , in which rearranging the synonymous codons comprises the step of randomly selecting and exchanging pairs of codons encoding the same amino acid and determining whether codon pair bias is reduced by the exchange. 3. The method of claim 2 , wherein the step is repeated until the codon pair bias is reduced by a desired amount. 4. The method of claim 2 , wherein the step is repeated until the codon pair bias converges on or near an optimal value. 5. The method of claim 1 , wherein steps (a) and (b) are implemented on a computer. 6. The method of claim 1 , wherein step (c) is achieved by de novo synthesis of the modified protein-encoding sequence. 7. The method of claim 6 , wherein the entire genome is substituted with the synthesized DNA. 8. The method of claim 6 , wherein a portion of the viral genome is substituted with the synthesized DNA. 9. The method of claim 1 , wherein the parent virus is a natural isolate. 10. The method of claim 1 , wherein the parent virus is a mutant of a natural isolate. 11. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias at least 0.1 less than the codon pair bias of the parent protein encoding sequence. 12. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias at least 0.2 less than the codon pair bias of the parent protein encoding sequence. 13. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias at least 0.3 less than the codon pair bias of the parent protein encoding sequence. 14. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias at least 0.4 less than the codon pair bias of the parent protein encoding sequence. 15. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias of −0.05 or less. 16. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias of −0.1 or less. 17. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias of −0.3 or less. 18. The method of claim 1 , wherein the modified protein encoding sequence has a codon pair bias of −0.4 or less. 19. The method of claim 1 , wherein the modified protein encoding sequence is modified over a length of at least 100 nucleotides. 20. The method of claim 1 , wherein the modified protein encoding sequence is modified over a length of at least 500 nucleotides. 21. The method of claim 1 , wherein the modified protein encoding sequence is modified over a length of at least 1000 nucleotides. 22. The method of claim 1 , wherein the parent virus is a poliovirus, rhinovirus, influenza virus, severe acute respiratory syndrome (SARS) coronavirus, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), infectious bronchitis virus, Ebolavirus, Marburg virus, dengue fever virus, West Nile disease virus, Epstein-Barr virus (EBV), yellow fever virus, Poxvirus, Herpes virus, Papillomavirus, or Adenovirus. 23. A method of making a modified virus comprising, making a modified viral genome according to the method of claim 1 ; and inserting the modified viral genome into a host cell, whereby a modified virus is produced. 24. The method of claim 1 , wherein the parent virus is a DNA, RNA, double-stranded, or single-stranded virus. 25. The method of claim 1 , wherein the modified viral genome is a DNA or an RNA nucleotide sequence.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10023845B2 cover?
This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provi…
Who is the assignee on this patent?
Univ New York State Res Found
What technology area does this patent fall under?
Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).